In early April 2025, Dhl announced the acquisition of the entire share capital of US-based Cryopdp, a company with expertise in the management of temperature-sensitive shipments for clinical trials, the biotech industry, and advanced therapeutic solutions. The move is part of the German group's strategy to position itself at the forefront of global healthcare logistics. In 2024, Dhl’s Life Sciences and Healthcare division generated revenues exceeding 5 billion euros. The acquisition of Cryopdp marks a further step in strengthening this position, enabling the group to expand its network of highly specialised pharmaceutical logistics services.
Headquartered in Nashville, Cryopdp operates in fifteen countries and handles over 600,000 shipments annually to more than 135 destinations worldwide. It is recognised for its "white-glove" services, which ensure high-reliability and tightly controlled transport for highly sensitive products, such as biological samples and innovative temperature-controlled medicines. The company will integrate with the air transport capabilities of Dhl Express and Dhl Global Forwarding, creating a system able to deliver end-to-end logistics solutions. Cryoport will in turn be able to focus on high-growth regions such as Asia-Pacific and the Emea area (Europe, the Middle East and Africa), while benefiting from Dhl’s global logistics strength.
